Send to

Choose Destination
Antiviral Res. 2016 Jun;130:81-92. doi: 10.1016/j.antiviral.2016.03.017. Epub 2016 Apr 4.

An inducible heat shock protein 70 small molecule inhibitor demonstrates anti-dengue virus activity, validating Hsp70 as a host antiviral target.

Author information

Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC, USA.
Emerging Infectious Diseases Program, Duke-NUS Graduate and Medical School, Singapore.
Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC, USA. Electronic address:


An estimated three billion people are at risk of Dengue virus (DENV) infection worldwide and there are currently no approved therapeutic interventions for DENV infection. Due to the relatively small size of the DENV genome, DENV is reliant on host factors throughout the viral life cycle. The inducible form of Heat Shock Protein 70 (Hsp70i) has been implicated as a host factor in DENV pathogenesis, however the complete role remains to be elucidated. Here we further illustrate the importance of Hsp70i in dengue virus pathogenesis and describe the antiviral activity of the allosteric small molecule inhibitor that is selective for Hsp70i, called HS-72. In monocytes, Hsp70i is expressed at low levels preceding DENV infection, but Hsp70i expression is induced upon DENV infection. Targeting Hsp70i with HS-72, results in a dose dependent reduction in DENV infected monocytes, while cell viability was maintained. HS-72 works to reduce DENV infection by inhibiting the entry stage of the viral life cycle, through disrupting the association of Hsp70i with the DENV receptor complex. This work highlights Hsp70i as an antiviral target and HS-72 as a potential anti-DENV therapeutic agent.


Antiviral target; Antiviral therapy; Dengue virus; Heat shock protein 70; Small molecule inhibitor

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center